These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 37572583)

  • 1. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing.
    Wakuda K; Morita M; Sekikawa M; Morikawa N; Miura K; Doshita K; Iida Y; Kodama H; Mamesaya N; Kobayashi H; Ko R; Ono A; Kenmotsu H; Naito T; Murakami H; Muramatsu K; Kawata T; Mori K; Shimizu T; Gon Y; Takahashi T
    Int J Clin Oncol; 2024 Feb; 29(2):96-102. PubMed ID: 38183554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation sequencing facilitates detection of the classic E13-A20 EML4-ALK fusion in an ALK-FISH/IHC inconclusive biopsy of a stage IV lung cancer patient: a case report.
    Volckmar AL; Endris V; Bozorgmehr F; Lier C; Porcel C; Kirchner M; Leichsenring J; Penzel R; Thomas M; Schirmacher P; Warth A; Stenzinger A
    Diagn Pathol; 2016 Nov; 11(1):133. PubMed ID: 27863497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma.
    Liu Z; Wu Q; Li W; Li P; Huang L; Wang T; Zhou Q
    Lung Cancer; 2023 Dec; 186():107386. PubMed ID: 37922771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catalog of 5' Fusion Partners in
    Ou SI; Zhu VW; Nagasaka M
    JTO Clin Res Rep; 2020 Mar; 1(1):100015. PubMed ID: 34589917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [ALK positive histiocytosis with multiple system involvement: report of a case].
    Yao S; Zhang F; Chen Y; Liu YH
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):495-497. PubMed ID: 38678335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fetal Lung Interstitial Tumor: A Comprehensive Case Study with an Emphasis on Next-Generation Sequencing.
    Jung YJ; Jung S; Koh J; Koh J; Jeon YK; Park SH; Kim EN; Kang CH
    J Chest Surg; 2024 Jul; 57(4):408-412. PubMed ID: 38378637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STRN::ALK, a novel fusion to foetal lung interstitial tumour.
    Paoli C; Di Mauro I; Coulomb A; Benadiba J; Lecompte JF; Dadone-Montaudié B; Burel-Vandenbos F
    Histopathology; 2024 Jun; ():. PubMed ID: 38859770
    [No Abstract]   [Full Text] [Related]  

  • 8. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
    Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
    J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
    Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
    Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel RSRC1-ALK (R6: A20) fusion using next-generation sequencing technique.
    Xia J; Chen S; Zhang Z; Wang J
    Cancer Genet; 2023 Nov; 278-279():18-23. PubMed ID: 37572583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W; Zhang J; Guo L; Chuai S; Shan L; Ying J
    J Thorac Oncol; 2017 Jan; 12(1):94-101. PubMed ID: 27614248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
    Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
    Ding Y; Sun C; Su W; Miao C; He X; Wang JS; Zhang ZH
    Virchows Arch; 2022 Sep; 481(3):405-419. PubMed ID: 35624360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib.
    Chen Y; Zhang X; Jiang Q; Wang B; Wang Y; Junrong Y
    Lung Cancer; 2020 Aug; 146():370-372. PubMed ID: 32527613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.